引用次数
引用: 47,495
H-指数: 94
I10-指数 : 280
出版物: 666
3-year results of docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer: a pilot study.
Antonio Fabiano Ferreira Filho , John Crown , Fatima Cardoso , Jean-Marie Nogaret
Anticancer Research 22 ( 4) 2471 -2476
5
2002
Gastric cancer metastatic to the pituitary gland: a case report.
Anna Maria Buccoliero , Angelo Di Leo , Chiara Pratesi , Rossana Fargnoli
Tumori 93 ( 2) 217 -219
11
2007
HER-2/neu evaluation by immunohistochemistry and fluorescence in situ hybridization in breast cancer: implications for daily laboratory practice.
Denis Larsimont , Angelo Di Leo , Ghizlane Rouas , Marianne Paesmans
Anticancer Research 22 ( 4) 2485 -2490
11
2002
Le traitement médical du cancer du sein: nouveaux espoirs à l'aube du 21ème siècle
Martine Piccart-Gebhart , Angelo Di Leo , Christos Sotiriou
Cancer Informatics 32 8 -12
2003
Docetaxel in the treatment of breast cancer: Current status, ongoing trials and future directions
Martine Piccart-Gebhart , Angelo Di Leo , Ahmad Awada , Dominique de Valeriola
Breast Cancer 257 -264
2
1996
Controversies in adjuvant systemic therapy of breast cancer. Part I: areas of controversy in the adjuvant systemic therapy of endocrine non-responsive breast cancer
Martine Piccart-Gebhart , Fatima Cardoso , Angelo Di Leo , Ahmad Awada
ASCO Educational Book 144 -155
4
2002
Breast Cancer: is there a new standard in adjuvant treatment ?
Martine Piccart-Gebhart , Angelo Di Leo
Annals of Oncology 7
1996
New Biological approaches to the treatment of cancer with a focus on breast cancer
Martine Piccart-Gebhart , Angelo Di Leo , Ahmad Awada
Bulletin Du Cancer 87 ( 1) 49 -62
2000
Bcl-2 as a predictive marker for tamoxifen responsiveness in the adjuvant setting of node-positive breast cancer
Fatima Cardoso , Angelo Di Leo , Denis Larsimont , Chantal Bernard
Breast Cancer Research and Treatment 69 ( 3) 243
3
2001
Nuovi farmaci interessanti nel trattamento del carcinoma ovarico ed in generale nei tumori della sfera ginecologica
Angelo Di Leo
Tumori 85 ( 3)
1999
Adjuvant chemotherapy in postmenopausal patients with early breast cancer: new clues after two decades of clinical research
Martine Piccart-Gebhart , Angelo Di Leo
South-American Journal of Cancer 1 ( 4) 226 -238
1998
Doxorubicin followed by docetaxel versus docetaxel followed by doxorubicin in the adjuvant treatment of node positive breast cancer: results of a feasibility study.
Fatima Cardoso , Antonio Fabiano Ferreira Filho , John Crown , Stella Dolci
Anticancer Research 21 789 -795
16
2001
p-53 gene mutations as a predictive marker in advanced breast cancer patients randomly treated either with doxorubicin or with docetaxel
Christine Desmedt , M Tanner , Angelo Di Leo , Marianne Paesmans
Breast Cancer Research and Treatment
2
2004
Clinical activity and cardiac tolerability of non-pegylated liposomal doxorubicin in breast cancer: a synthetic review.
Marzia Lotrionte , Saverio Cinieri , Maria Teresa Ionta , Giorgio Minotti
Tumori 97 ( 6) 690 -692
20
2011
HER-2 Amplification and Topoisomerase IIα Gene Aberrations as Predictive Markers in Node-positive Breast Cancer Patients Randomly Treated Either with an Anthracycline-based Therapy or with Cyclophosphamide, Methotrexate, and 5-Fluorouracil
David Gancberg , Jorma Isola , Martine J. Piccart , Denis Larsimont
Clinical Cancer Research 8 ( 5) 1107 -1116
259
2002
Polysomy 17 in HER-2/neu Status Elaboration in Breast Cancer: Impact in Daily Practice
Martine Piccart-Gebhart , Laurence Lespagnard , Isabelle Veys , Denis Larsimont
Proceedings of the American Association for Cancer Research
2005
Actualités thérapeutiques dans le cancer du sein
Martine J. Piccart , Angelo Di Leo , Ahmad Awada
Bulletin Du Cancer 87 ( 1) 49 -62
1
2000
Topoisomerase II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated with single-agent doxorubicin or single-agent docetaxel
Christine Desmedt , Virginie Durbecq , Marianne Paesmans , Christos Sotiriou
Cancer Research 64 263 -263
45
2004
BELLE-3: A Phase III study of the pan-phosphatidylinositol 3-kinase (PI3K) inhibitor buparlisib (BKM120) with fulvestrant in postmenopausal women with HR+/HER2- locally advanced/metastatic breast cancer (BC) pretreated with aromatase inhibitors (AIs) and refractory to mTOR inhibitor (mTORi)-based treatment.
Thomas Denis Bachelot , Eva Ciruelos , Per Eystein Lonning , Mona El-Hashimy
Journal of Clinical Oncology 33
4
2015
MONARCH 3: A randomized phase III study of anastrozole or letrozole plus abemaciclib, a CDK4/6 inhibitor, or placebo in first-line treatment of women with HR+, HER2-locoregionally recurrent or metastatic breast cancer (MBC).
Suzanne Klise , Nawel Bourayou , Martin Frenzel , Angelo Di Leo
Journal of Clinical Oncology 33
8
2015